Cutanos

Cutanos is an Austria-based biotech company developing targeted immune therapies using its Langerhans Cell Targeted Delivery System (LC-TDS), a ligand-based platform designed to direct cargos specifically to skin-resident Langerhans cells. The company is applying this platform to antigen-specific vaccines and immunotherapies, including approaches for autoimmune disease tolerance induction and next-generation vaccine applications. Cutanos has reported preclinical work in both protein and mRNA delivery, including Langerhans cell-targeted lipid nanoparticle formulations intended to improve immune precision, enable dose sparing, and reduce off-target effects. The company originated as a spin-off from the Max Planck Institute of Colloids and Interfaces and is backed by early-stage investors in Austria and Germany. Its programs appear to remain in preclinical development, with the platform positioned for applications across autoimmunity, infectious disease, allergy, and oncology.